Show simple item record

dc.contributor.authorRøsland, Gro Vatneeng
dc.contributor.authorEngelsen, Agnete Svendsen Tenfjordeng
dc.date.accessioned2014-11-04T07:47:10Z
dc.date.available2014-11-04T07:47:10Z
dc.date.issued2015-01eng
dc.identifier.issn1742-7835eng
dc.identifier.otherPMID: 25154903eng
dc.identifier.urihttp://hdl.handle.net/1956/8706
dc.description.abstractNew molecular insight reveals novel points of attack for targeted cancer therapy. The recent advances in cancer genomics and novel insight into the complex biology of cancer make the promise of personalized, targeted cancer medicine closer than ever. The massive parallel sequencing endeavours performed by The Cancer Genome Atlas, the International Cancer Genome Consortium and by numerous individual investigators have provided a comprehensive genomic characterization of a wide range of cancers. The joint efforts enabled by the improved sequencing technology have demonstrated that individual cancers comprise mutational repertoires with only a few frequently recurrent driver genes. Thus, the identification of new drug targets and novel drugs have accelerated and renewed the hopes of personalized cancer therapy achieving clinical reality for a wider range of cancers. Together with cost-effective sequencing technology to perform comprehensive mutational profiling of each individual cancer, this provides the basis for a personalized cancer medicine revolution within the next few years. The aim of this MiniReview is to provide an overview of the history and evolution of targeted cancer therapy, exemplified by molecularly targeted drugs successfully implemented in the clinic. Furthermore, we aim to highlight novel molecular targets for therapeutic intervention, as well as the main present challenges including inter- and intratumor heterogeneity and cellular plasticity in addition to the importance of the tumor micro-environment. Many cancer patients already receive some form of tailored therapy, and recent evidence suggests that novel and highly innovative, targeted approaches are on their way into the clinic.en_US
dc.language.isoengeng
dc.publisherWileyeng
dc.publisherNordic Pharmacological Societyeng
dc.rightsAttribution-NonCommercial CC BY-NCeng
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/eng
dc.subjecttargeted cancer therapyeng
dc.titleNovel Points of Attack for Targeted Cancer Therapyeng
dc.typeJournal articleeng
dc.rights.holderCopyright 2014 The Authors
dc.type.versionpublishedVersioneng
bora.peerreviewedPeer reviewedeng
bora.journalTitleBasic and Clinical Pharmacology and Toxicologyeng
bibo.volume116eng
bibo.issue1eng
bibo.pageStart9eng
bibo.pageEnd18eng
bibo.eissn1742-7843eng
bibo.doihttp://dx.doi.org/10.1111/bcpt.12313eng
bora.accessRightsinfo:eu-repo/semantics/openAccesseng
dc.identifier.doi10.1111/bcpt.12313
bora.bpoaIDbpoa215


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial CC BY-NC
Except where otherwise noted, this item's license is described as Attribution-NonCommercial CC BY-NC